Aventis and Schering AG have entered into exclusive negotiations with Bayer to sell Aventis CropScience. Aventis holds a 76% interest and Schering owns 24%. Aventis would use the funds to pay down debt. Schering plans to put funds from the sale towards acquisitions or in-licensing arrangements
You may also be interested in...
Berlex plans to pursue a Crohn's disease indication for Leukine (sargramostim) following acquisition of the product from Immunex
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011